162 related articles for article (PubMed ID: 9756756)
21. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
[TBL] [Abstract][Full Text] [Related]
22. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Kirk M; Hill RL; Casewell MW; Beighton D
Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
[No Abstract] [Full Text] [Related]
23. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
Williams JD; Maskell JP; Whiley AC; Sefton AM
J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
[TBL] [Abstract][Full Text] [Related]
24. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.
Lefort A; Saleh-Mghir A; Garry L; Carbon C; Fantin B
Antimicrob Agents Chemother; 2000 Nov; 44(11):3017-21. PubMed ID: 11036016
[TBL] [Abstract][Full Text] [Related]
25. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.
Eliopoulos GM; Wennersten CB; Gold HS; Schülin T; Souli M; Farris MG; Cerwinka S; Nadler HL; Dowzicky M; Talbot GH; Moellering RC
Antimicrob Agents Chemother; 1998 May; 42(5):1088-92. PubMed ID: 9593132
[TBL] [Abstract][Full Text] [Related]
26. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
Kang SL; Rybak MJ
J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
[TBL] [Abstract][Full Text] [Related]
27. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
Lorian V; Fernandes F
Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
[TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium.
Bonilla HF; Perri MB; Kauffman CA; Zervos MJ
Diagn Microbiol Infect Dis; 1996 Jul; 25(3):127-31. PubMed ID: 8902408
[TBL] [Abstract][Full Text] [Related]
29. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.
Lorian V; Fernandes F
J Antimicrob Chemother; 1997 May; 39 Suppl A():63-6. PubMed ID: 9511065
[TBL] [Abstract][Full Text] [Related]
30. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.
Louie A; Baltch AL; Ritz WJ; Smith RP; Asperilla M
Chemotherapy; 1993; 39(5):302-9. PubMed ID: 8396526
[TBL] [Abstract][Full Text] [Related]
31. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium.
Fraimow HS; Venuti E
Antimicrob Agents Chemother; 1992 Jul; 36(7):1563-6. PubMed ID: 1510455
[TBL] [Abstract][Full Text] [Related]
32. Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium.
Aligholi M; Emaneini M; Taherikalani M; Shahsavan S; Jabalameli F; Asadollahi P; Khoramian B; Eslampour MA
Acta Microbiol Immunol Hung; 2011 Sep; 58(3):219-26. PubMed ID: 21983323
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.
Aeschlimann JR; Rybak MJ
Antimicrob Agents Chemother; 1998 Sep; 42(9):2188-92. PubMed ID: 9736533
[TBL] [Abstract][Full Text] [Related]
34. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin.
Landman D; Mobarakai NK; Quale JM
Antimicrob Agents Chemother; 1993 Sep; 37(9):1904-8. PubMed ID: 8239604
[TBL] [Abstract][Full Text] [Related]
35. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Stumpo C; Rybak MJ
J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
[TBL] [Abstract][Full Text] [Related]
36. Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci.
Tripodi MF; Utili R; Rambaldi A; Locatelli A; Rosario P; Florio A; Ruggiero G
J Antimicrob Chemother; 1996 Apr; 37(4):727-36. PubMed ID: 8722538
[TBL] [Abstract][Full Text] [Related]
37. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.
Sakoulas G; Bayer AS; Pogliano J; Tsuji BT; Yang SJ; Mishra NN; Nizet V; Yeaman MR; Moise PA
Antimicrob Agents Chemother; 2012 Feb; 56(2):838-44. PubMed ID: 22123698
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
Jones RN; Barrett MS; Erwin ME
Antimicrob Agents Chemother; 1997 Feb; 41(2):488-93. PubMed ID: 9021216
[TBL] [Abstract][Full Text] [Related]
39. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
[TBL] [Abstract][Full Text] [Related]
40. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
Caron F; Gold HS; Wennersten CB; Farris MG; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 1997 Dec; 41(12):2749-53. PubMed ID: 9420051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
